Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...
就在昨天，新加坡国立大学、中国人民大学、复旦大学等多所顶尖机构联合发布了一篇AI Agent 记忆（Memory）综述。 当前的 LLM 应用开发正面临严重的“记忆碎片化”问题：我们有用于短期记忆的 KV Cache，有用于知识检索的 RAG，还有用于长期交互的 MemGPT 类架构，但缺乏统一的理论指导。这篇综述不仅是对现有工作的盘点，更是一份解决“灾难性遗忘”与“上下文溢出”的系统方案。它详细 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈